The USA-based company has developed a high-quality protein production and bioanalytic technology platform approach, that allows it to create biosimilars in an efficient manner.

It is one of few companies focused on non-glycosylated biosimilars, creating a differentiated platform approach and competitive advantage. This ensures a robust pipeline of high-quality therapeutics.

In addition, its unique protein production platform is well-suited to vaccine development. The organization is able to rapidly identify production strains for antigens that cannot be readily produced in other systems, which enables infectious disease research and vaccine development that was previously not possible.